Guangzhou Junxin Pharmaceutical

Guangzhou Junxin Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology. The company focuses on targeting the cell cycle, with a robust pipeline of next-generation cyclin-dependent kinase (CDK) inhibitors designed to overcome resistance to existing therapies. Its lead candidate, JX-05, is a highly selective CDK4/6 inhibitor currently in Phase 2 clinical trials for advanced breast cancer. Junxin is also advancing JX-08, a CDK7 inhibitor, and JX-09, a multi-CDK inhibitor, to address a variety of solid tumors. Founded by industry veterans with experience at global pharmaceutical firms, the company aims to provide high-quality, affordable precision medicines to patients worldwide.